Stakeholder Opinions: Heart Failure - When drugs do not work

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the cardiovascular analysis team
• CHAPTER 1 EXECUTIVE SUMMARY
  • Scope of the analysis
  • Datamonitor insight into available therapies in advancedheart failure
  • Contributing experts
• CHAPTER 2 HEART FAILURE DEFINITIONS AND PATHOPHYSIOLOGY
  • Definition of heart failure
    • Acute heart failure
    • Chronic heart failure
  • Etiology of heart failure
    • Segmentation of heart failure
      • Disease severity
      • Low versus high output failure
      • Systolic versus diastolic heart failure
      • Age group
  • Co-morbidities, complications and risk factors
• CHAPTER 3 EPIDEMIOLOGY
  • Epidemiology of heart failure
    • Future incidence of acute heart failure
    • Future prevalence of chronic heart failure
  • Future trends in the incidence and prevalence of heartfailure
• CHAPTER 4 DIAGNOSIS AND INVESTIGATION
  • Diagnosis
    • Symptoms
    • Neurohormonal activation markers
    • Novel biomarkers
  • Role of medical imaging in heart failure
    • Chest x-ray
    • Echocardiography
    • Nuclear perfusion tests
    • Role of MRI in coronary heart disease diagnosis
• CHAPTER 5 BASIC PHARMACOLOGICAL THERAPY
  • Drug classes in heart failure
    • ACE inhibitors
    • Angiotensin II receptor blockers
    • Diuretics
    • Betablockers
    • Digoxin
    • Antithrombotics
    • Calcium channel blockers
• CHAPTER 6 DEVICE THERAPIES IN HEART FAILURE
  • Treatment options in advanced heart failure
    • Heart transplantation
    • Fundamental differences between drugs and devices
  • Arrhythmia Devices in Heart Failure
    • Ventricular dyssynchrony
    • Role of ICD therapy
      • Historical development of ICD device therapy
      • Indications and guidelines for ICD therapy
    • Cardiac resynchronization therapy
      • CRT-P vs. CRT-D vs. ICD
      • Limitations of cardiac resynchronization therapy
      • Guidelines and indications
    • Novel technologies
      • Prevention with advanced biosensors
      • Less invasion with leadless technology
      • Cardiac contractility modulation therapy
  • Mechanical circulatory support devices
    • Ventricular Assist Devices
      • Historical developments and design transformation
      • Pulsatile design
      • Rotary design and continuous flow
      • Guidelines and indications for mechanical assistance
    • Total artificial heart devices
    • Counterpulsation devices without blood contact
    • Short-term mechanical assistance
      • Extracorporeal membrane oxygenation (ECMO)
      • Intra-aortic Balloon Pumps
      • Percutaneous transseptal circulatory assist devices
    • Passive containment devices
      • Future technology with artificial heart muscle
    • Problems associated with mechanical circulatory assistdevices
      • Biocompatibility, coagulation control and device surfaces
      • Infection and external components
      • Power sources, size and patient mobility
      • Mechanical durability
    • Future directions and industry challenges
      • Summary of design trends
      • Telemedicine for heart failure management
      • Device availability
      • FDA approved devices
• APPENDIX A
  • Methodology
    • Epidemiology
      • Incidence of acute heart failure
      • Prevalence of chronic heart failure
• APPENDIX B
  • Report methodology
  • Bibliography
• APPENDIX C
  • About Datamonitor
  • About Datamonitor Healthcare
  • About the cardiovascular analysis team
  • Disclaimer
• List of Tables
  • Table 1: Causes of heart failure in the seven majormarkets (%), 2004
  • Table 2: Prevalence of chronic heart failure by agegroup in the seven major markets (000s), 2005
  • Table 3: Estimated proportion of chronic heart failurepatients with co-morbid conditions and risk factors in the seven majormarkets (%), 2004
  • Table 4: Estimated incidence of acute heart failure inthe seven major markets (000s), 2008-2016
  • Table 5: Future estimated incidence of chronic heartfailure in the seven major markets (000s), 2008-2016
  • Table 6: Symptoms used in the diagnosis of chronic heartfailure in the seven major markets, 2004
  • Table 7: Symptoms observed in chronic heart failurepatients in the seven major markets, 2004
  • Table 8: Tests used in the diagnosis of chronic heartfailure in the seven major markets, 2004
  • Table 9: Proportion of patients with chronic heartfailure receiving each diagnostic test, 2004
  • Table 10: Historical development of ICD device therapy
  • Table 11: Major clinical trials for CRT
  • Table 12: Indications for CRT-D vs. ICD
• List of Figures
  • Figure 1: Segmentation of diagnosed chronic heartfailure patients by disease severity, 2004
  • Figure 2: ACC/AHA practice guidelines for the evaluationand management of chronic heart failure, 2005
  • Figure 3: Relationship between cardiac dysfunction,heart failure and heart failure rendered asymptomatic, as defined by theEuropean Society of Cardiology
  • Figure 4: Breakdown of heart failure patients accordingto whether failure is systolic, diastolic or both in 7MM, 2004
  • Figure 5: Staging of heart failure and associatedinterventions
  • Figure 6: Prevalence of atrial fibrillation (AF) inheart failure patients
  • Figure 7: Current CRT devices
  • Figure 8: Ventricular assist devices and components
  • Figure 9: Types of ventricular assist devices
  • Figure 10: Modern pulatile ventricular assist pump
  • Figure 11: Centrifugal flow ventricular assist system
  • Figure 12: Jarvik Heart
  • Figure 13: HeartMate II
  • Figure 14: INCOR BerlinHeart
  • Figure 15: CardioWest Total Artificial Heart
  • Figure 16: Examples of counterpulsation devices
  • Figure 17: TandemHeart pVAD
  • Figure 18: Acorn CorCap
  • Figure 19: Type and rates of device-relatedcomplications